Bosun Asset Management LLC Sells 11,766 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Bosun Asset Management LLC decreased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 15.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 64,470 shares of the biotechnology company's stock after selling 11,766 shares during the period. Bosun Asset Management LLC's holdings in ADMA Biologics were worth $1,106,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in ADMA. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in ADMA Biologics by 1.3% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock worth $865,000 after purchasing an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund raised its holdings in shares of ADMA Biologics by 1.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after buying an additional 700 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in ADMA Biologics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock worth $404,000 after buying an additional 746 shares during the last quarter. Mutual of America Capital Management LLC boosted its stake in ADMA Biologics by 2.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after buying an additional 751 shares in the last quarter. Finally, Maryland State Retirement & Pension System grew its position in ADMA Biologics by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock valued at $1,365,000 after acquiring an additional 897 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Raymond James upped their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Trading Down 5.7 %

Shares of NASDAQ ADMA traded down $1.21 during mid-day trading on Friday, hitting $19.99. The stock had a trading volume of 4,137,195 shares, compared to its average volume of 3,750,109. The business has a 50 day moving average price of $20.17 and a two-hundred day moving average price of $18.69. ADMA Biologics, Inc. has a 1 year low of $7.96 and a 1 year high of $25.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market cap of $4.75 billion, a P/E ratio of 71.39 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business's revenue was up 40.2% on a year-over-year basis. During the same period last year, the company posted $0.08 earnings per share. On average, equities analysts anticipate that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.